CLOs on the Move

Chartiers Center

www.chartierscenter.org

 
Chartiers’ primary focus is the integration of physical health and mental health wellness to enhance the quality of life for all people with behavioral or intellectual/ and developmental disabilities. Chartiers operates programs for adults with inte...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

Novadoz

Novadoz Pharmaceuticals is a sales and marketing subsidiary for MSN Labs portfolio of finished dosage forms. MSN Labs is a global leader in the development and manufacturing of APIs (active pharmaceutical ingredients).

Sanford House

Sanford House in Grand Rapids, Michigan is a drug and alcohol rehab and recovery center. We offer residential and non-residential treatment options for both men and women in Michigan and across the country. Our Johns Street location provides detox for ...

Nautilus Biosciences Canada

Nautilus Biosciences Canada is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Tetraphase

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.